{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:16:08Z","timestamp":1790403368561,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Secretaria de Ciencia Tecnolog\u00eda e Innovaci\u00f3n de la Ciudad de Mexico","award":["037-2016"],"award-info":[{"award-number":["037-2016"]}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2016-78207R"],"award-info":[{"award-number":["SAF2016-78207R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["PCIN 2015-098"],"award-info":[{"award-number":["PCIN 2015-098"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003751","name":"Ministerio de Sanidad, Servicios Sociales e Igualdad","doi-asserted-by":"publisher","award":["PNSD 2016\/33"],"award-info":[{"award-number":["PNSD 2016\/33"]}],"id":[{"id":"10.13039\/501100003751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","award":["172275"],"award-info":[{"award-number":["172275"]}],"id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12035-018-1356-6","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T22:29:05Z","timestamp":1538000945000},"page":"4037-4050","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates l-DOPA-Induced Dyskinesia in Aphakia Mice"],"prefix":"10.1007","volume":"56","author":[{"given":"Jos\u00e9-Rub\u00e9n","family":"Garc\u00eda-Montes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Sol\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Enr\u00edquez-Traba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ruiz-DeDiego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Drucker-Col\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7623-8010","authenticated-orcid":false,"given":"Rosario","family":"Moratalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"1356_CR1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1056\/NEJM196702162760703","volume":"276","author":"GC Cotzias","year":"1967","unstructured":"Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of Parkinsonism. N Engl J Med 276:374\u2013379. https:\/\/doi.org\/10.1056\/NEJM196702162760703","journal-title":"N Engl J Med"},{"key":"1356_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.pneurobio.2016.07.002","volume":"151","author":"P Deurwaerd\u00e8re De","year":"2017","unstructured":"De Deurwaerd\u00e8re P, Di Giovanni G, Millan MJ (2017) Expanding the repertoire of L-DOPA\u2019s actions: a comprehensive review of its functional neurochemistry. Prog Neurobiol 151:57\u2013100. https:\/\/doi.org\/10.1016\/j.pneurobio.2016.07.002","journal-title":"Prog Neurobiol"},{"key":"1356_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2174\/1871527311201070897","volume":"11","author":"JR Garc\u00eda-Montes","year":"2012","unstructured":"Garc\u00eda-Montes JR, Boronat-Garc\u00eda A, L\u00f3pez-Colom\u00e9 AM et al (2012) Is nicotine protective against Parkinson\u2019s disease? An experimental analysis. CNS Neurol Disord Drug Targets 11:897\u2013906","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1356_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/jnc.12751","volume":"130","author":"R Heumann","year":"2014","unstructured":"Heumann R, Moratalla R, Herrero MT, Chakrabarty K, Drucker-Col\u00edn R, Garcia-Montes JR, Simola N, Morelli M (2014) Dyskinesia in Parkinson\u2019s disease: mechanisms and current non-pharmacological interventions. J Neurochem 130:472\u2013489. https:\/\/doi.org\/10.1111\/jnc.12751","journal-title":"J Neurochem"},{"key":"1356_CR5","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00702-018-1852-x","volume":"125","author":"O Sol\u00eds","year":"2018","unstructured":"Sol\u00eds O, Moratalla R (2018) Dopamine receptors: homomeric and heteromeric complexes in L-DOPA-induced dyskinesia. J Neural Transm 125:1187\u20131194. https:\/\/doi.org\/10.1007\/s00702-018-1852-x","journal-title":"J Neural Transm"},{"key":"1356_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/archneur.58.2.249","volume":"58","author":"O Rascol","year":"2001","unstructured":"Rascol O, Nutt JG, Blin O, Goetz CG, Trugman JM, Soubrouillard C, Carter JH, Currie LJ et al (2001) Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 58:249\u2013254","journal-title":"Arch Neurol"},{"key":"1356_CR7","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.nbd.2007.02.001","volume":"26","author":"C Guigoni","year":"2007","unstructured":"Guigoni C, Doudnikoff E, Li Q, Bloch B, Bezard E (2007) Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis 26:452\u2013463. https:\/\/doi.org\/10.1016\/j.nbd.2007.02.001","journal-title":"Neurobiol Dis"},{"key":"1356_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.biopsych.2009.04.025","volume":"66","author":"S Darmopil","year":"2009","unstructured":"Darmopil S, Mart\u00edn AB, De Diego IR et al (2009) Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 66:603\u2013613. https:\/\/doi.org\/10.1016\/j.biopsych.2009.04.025","journal-title":"Biol Psychiatry"},{"key":"1356_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3233\/JPD-2011-11068","volume":"1","author":"HS Lindgren","year":"2011","unstructured":"Lindgren HS, Rylander D, Iderberg H et al (2011) Putaminal upregulation of FosB\/\u0394FosB-like immunoreactivity in Parkinson\u2019s disease patients with dyskinesia. J Parkinsons Dis 1:347\u2013357. https:\/\/doi.org\/10.3233\/JPD-2011-11068","journal-title":"J Parkinsons Dis"},{"key":"1356_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.nbd.2012.07.012","volume":"48","author":"I Espadas","year":"2012","unstructured":"Espadas I, Darmopil S, Verga\u00f1o-Vera E, Ortiz O, Oliva I, Vicario-Abej\u00f3n C, Mart\u00edn ED, Moratalla R (2012) L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function. Neurobiol Dis 48:271\u2013281. https:\/\/doi.org\/10.1016\/j.nbd.2012.07.012","journal-title":"Neurobiol Dis"},{"key":"1356_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.pbb.2016.04.001","volume":"145","author":"V Palafox-S\u00e1nchez","year":"2016","unstructured":"Palafox-S\u00e1nchez V, Mendieta L, Ram\u00edrez-Garc\u00eda G, Candalija A, Aguilera J, Lim\u00f3n ID (2016) Effect of the C-terminal domain of the heavy chain of tetanus toxin on dyskinesia caused by levodopa in 6-hydroxydopamine-lesioned rats. Pharmacol Biochem Behav 145:33\u201344. https:\/\/doi.org\/10.1016\/j.pbb.2016.04.001","journal-title":"Pharmacol Biochem Behav"},{"key":"1356_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.nbd.2017.03.006","volume":"102","author":"O Sol\u00eds","year":"2017","unstructured":"Sol\u00eds O, Garc\u00eda-Montes JR, Garcia-Sanz P, Herranz AS, Asensio MJ, Kang G, Hiroi N, Moratalla R (2017) Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice. Neurobiol Dis 102:133\u2013139. https:\/\/doi.org\/10.1016\/j.nbd.2017.03.006","journal-title":"Neurobiol Dis"},{"key":"1356_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/cercor\/bhv231","volume":"27","author":"O Sol\u00eds","year":"2017","unstructured":"Sol\u00eds O, Garcia-Montes JR, Gonz\u00e1lez-Granillo A, Xu M, Moratalla R (2017) Dopamine D3 receptor modulates l-DOPA-induced dyskinesia by targeting D1 receptor-mediated striatal signaling. Cereb Cortex 27:435\u2013446. https:\/\/doi.org\/10.1093\/cercor\/bhv231","journal-title":"Cereb Cortex"},{"key":"1356_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.biopsych.2014.03.023","volume":"77","author":"I Ruiz-DeDiego","year":"2015","unstructured":"Ruiz-DeDiego I, Mellstrom B, Vallejo M, Naranjo JR, Moratalla R (2015) Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice. Biol Psychiatry 77:95\u2013105. https:\/\/doi.org\/10.1016\/j.biopsych.2014.03.023","journal-title":"Biol Psychiatry"},{"key":"1356_CR15","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1523\/JNEUROSCI.2702-13.2014","volume":"34","author":"T Fieblinger","year":"2014","unstructured":"Fieblinger T, Sebastianutto I, Alcacer C, Bimpisidis Z, Maslava N, Sandberg S, Engblom D, Cenci MA (2014) Mechanisms of dopamine D1 receptor-mediated ERK1\/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5. J Neurosci 34:4728\u20134740. https:\/\/doi.org\/10.1523\/JNEUROSCI.2702-13.2014","journal-title":"J Neurosci"},{"key":"1356_CR16","doi-asserted-by":"publisher","first-page":"107ra109","DOI":"10.1126\/scitranslmed.3003062","volume":"3","author":"A Levine","year":"2011","unstructured":"Levine A, Huang Y, Drisaldi B, Griffin EA, Pollak DD, Xu S, Yin D, Schaffran C et al (2011) Molecular mechanism for a gateway drug: epigenetic changes initiated by nicotine prime gene expression by cocaine. Sci Transl Med 3:107ra109. https:\/\/doi.org\/10.1126\/scitranslmed.3003062","journal-title":"Sci Transl Med"},{"issue":"Pt 2","key":"1356_CR17","first-page":"433","volume":"116","author":"P Calabresi","year":"1993","unstructured":"Calabresi P, Mercuri NB, Sancesario G, Bernardi G (1993) Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson\u2019s disease. Brain 116(Pt 2):433\u2013452","journal-title":"Brain"},{"key":"1356_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1006\/exnr.2002.7900","volume":"175","author":"CK Meshul","year":"2002","unstructured":"Meshul CK, Kamel D, Moore C, Kay TS, Krentz L (2002) Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats. Exp Neurol 175:257\u2013274. https:\/\/doi.org\/10.1006\/exnr.2002.7900","journal-title":"Exp Neurol"},{"key":"1356_CR19","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1093\/cercor\/bhw263","volume":"26","author":"LM Suarez","year":"2016","unstructured":"Suarez LM, Solis O, Aguado C, Lujan R, Moratalla R (2016) L-DOPA oppositely regulates synaptic strength and spine morphology in D1 and D2 striatal projection neurons in dyskinesia. Cereb Cortex 26:4253\u20134264. https:\/\/doi.org\/10.1093\/cercor\/bhw263","journal-title":"Cereb Cortex"},{"key":"1356_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12640-016-9612-x","volume":"30","author":"O Sol\u00eds","year":"2016","unstructured":"Sol\u00eds O, Garc\u00eda-Sanz P, Herranz AS, Asensio MJ, Moratalla R (2016) L-DOPA reverses the increased free amino acids tissue levels induced by dopamine depletion and rises GABA and tyrosine in the striatum. Neurotox Res 30:67\u201375. https:\/\/doi.org\/10.1007\/s12640-016-9612-x","journal-title":"Neurotox Res"},{"key":"1356_CR21","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1111\/j.1460-9568.2005.04498.x","volume":"22","author":"A Oueslati","year":"2005","unstructured":"Oueslati A, Breysse N, Amalric M, Kerkerian-le Goff L, Salin P (2005) Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early Parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism. Eur J Neurosci 22:2765\u20132774. https:\/\/doi.org\/10.1111\/j.1460-9568.2005.04498.x","journal-title":"Eur J Neurosci"},{"key":"1356_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/cne.903540207","volume":"354","author":"CM Testa","year":"1995","unstructured":"Testa CM, Standaert DG, Landwehrmeyer GB, Penney JB, Young AB (1995) Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons. J Comp Neurol 354:241\u2013252. https:\/\/doi.org\/10.1002\/cne.903540207","journal-title":"J Comp Neurol"},{"key":"1356_CR23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nrn1763","volume":"6","author":"PJ Conn","year":"2005","unstructured":"Conn PJ, Battaglia G, Marino MJ, Nicoletti F (2005) Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 6:787\u2013798. https:\/\/doi.org\/10.1038\/nrn1763","journal-title":"Nat Rev Neurosci"},{"key":"1356_CR24","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/mds.25920","volume":"29","author":"E Bezard","year":"2014","unstructured":"Bezard E, Pioli EY, Li Q, Girard F, Mutel V, Keywood C, Tison F, Rascol O et al (2014) The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Mov Disord 29:1074\u20131079. https:\/\/doi.org\/10.1002\/mds.25920","journal-title":"Mov Disord"},{"key":"1356_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.parkreldis.2011.01.008","volume":"17","author":"L Gr\u00e9goire","year":"2011","unstructured":"Gr\u00e9goire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S et al (2011) The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord 17:270\u2013276. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.01.008","journal-title":"Parkinsonism Relat Disord"},{"key":"1356_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.nbd.2007.08.011","volume":"29","author":"G Levandis","year":"2008","unstructured":"Levandis G, Bazzini E, Armentero MT, Nappi G, Blandini F (2008) Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson\u2019s disease. Neurobiol Dis 29:161\u2013168. https:\/\/doi.org\/10.1016\/j.nbd.2007.08.011","journal-title":"Neurobiol Dis"},{"key":"1356_CR27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","volume":"101","author":"F Mela","year":"2007","unstructured":"Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson\u2019s disease. J Neurochem 101:483\u2013497. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.04456.x","journal-title":"J Neurochem"},{"key":"1356_CR28","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.neurobiolaging.2009.07.014","volume":"32","author":"B Ouattara","year":"2011","unstructured":"Ouattara B, Gr\u00e9goire L, Morissette M, Gasparini F, Vranesic I, Bilbe G, Johns DR, Rajput A et al (2011) Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 32:1286\u20131295. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2009.07.014","journal-title":"Neurobiol Aging"},{"key":"1356_CR29","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1016\/j.bmc.2014.09.033","volume":"22","author":"I Vranesic","year":"2014","unstructured":"Vranesic I, Ofner S, Flor PJ, Bilbe G, Bouhelal R, Enz A, Desrayaud S, McAllister K et al (2014) AFQ056\/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization. Bioorg Med Chem 22:5790\u20135803. https:\/\/doi.org\/10.1016\/j.bmc.2014.09.033","journal-title":"Bioorg Med Chem"},{"key":"1356_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neurobiolaging.2017.09.006","volume":"61","author":"M Crabb\u00e9","year":"2018","unstructured":"Crabb\u00e9 M, Van der Perren A, Weerasekera A et al (2018) Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson\u2019s disease and levodopa-induced dyskinesia. Neurobiol Aging 61:82\u201392. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.09.006","journal-title":"Neurobiol Aging"},{"key":"1356_CR31","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/mds.26659","volume":"31","author":"F Tison","year":"2016","unstructured":"Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S et al (2016) A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson\u2019s disease. Mov Disord 31:1373\u20131380. https:\/\/doi.org\/10.1002\/mds.26659","journal-title":"Mov Disord"},{"key":"1356_CR32","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/mds.26585","volume":"31","author":"C Trenkwalder","year":"2016","unstructured":"Trenkwalder C, Stocchi F, Poewe W, Dronamraju N, Kenney C, Shah A, von Raison F, Graf A (2016) Mavoglurant in Parkinson\u2019s patients with l-Dopa-induced dyskinesias: two randomized phase 2 studies. Mov Disord 31:1054\u20131058. https:\/\/doi.org\/10.1002\/mds.26585","journal-title":"Mov Disord"},{"key":"1356_CR33","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.4103\/0366-6999.211555","volume":"130","author":"JJ Du","year":"2017","unstructured":"Du JJ, Chen SD (2017) Current nondopaminergic therapeutic options for motor symptoms of Parkinson\u2019s disease. Chin Med J 130:1856\u20131866. https:\/\/doi.org\/10.4103\/0366-6999.211555","journal-title":"Chin Med J"},{"key":"1356_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2004.12.003","volume":"231","author":"J Reuck De","year":"2005","unstructured":"De Reuck J, De Weweire M, Van Maele G, Santens P (2005) Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson\u2019s disease. J Neurol Sci 231:35\u201339. https:\/\/doi.org\/10.1016\/j.jns.2004.12.003","journal-title":"J Neurol Sci"},{"key":"1356_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1124\/jpet.108.140897","volume":"327","author":"T Bordia","year":"2008","unstructured":"Bordia T, Campos C, Huang L, Quik M (2008) Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson\u2019s disease. J Pharmacol Exp Ther 327:239\u2013247. https:\/\/doi.org\/10.1124\/jpet.108.140897","journal-title":"J Pharmacol Exp Ther"},{"key":"1356_CR36","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1124\/jpet.111.182949","volume":"338","author":"LZ Huang","year":"2011","unstructured":"Huang LZ, Grady SR, Quik M (2011) Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors. J Pharmacol Exp Ther 338:932\u2013941. https:\/\/doi.org\/10.1124\/jpet.111.182949","journal-title":"J Pharmacol Exp Ther"},{"key":"1356_CR37","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.bcp.2013.06.027","volume":"86","author":"M Quik","year":"2013","unstructured":"Quik M, Campos C, Grady SR (2013) Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice. Biochem Pharmacol 86:1153\u20131162. https:\/\/doi.org\/10.1016\/j.bcp.2013.06.027","journal-title":"Biochem Pharmacol"},{"key":"1356_CR38","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/mds.25594","volume":"28","author":"M Quik","year":"2013","unstructured":"Quik M, Mallela A, Ly J, Zhang D (2013) Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson\u2019s disease. Mov Disord 28:1398\u20131406. https:\/\/doi.org\/10.1002\/mds.25594","journal-title":"Mov Disord"},{"key":"1356_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pharmthera.2014.05.004","volume":"144","author":"M Quik","year":"2014","unstructured":"Quik M, Zhang D, Perez XA, Bordia T (2014) Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther 144:50\u201359. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.05.004","journal-title":"Pharmacol Ther"},{"key":"1356_CR40","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ana.21203","volume":"62","author":"M Quik","year":"2007","unstructured":"Quik M, Cox H, Parameswaran N, O\u2019Leary K, Langston JW, di Monte D (2007) Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 62:588\u2013596. https:\/\/doi.org\/10.1002\/ana.21203","journal-title":"Ann Neurol"},{"key":"1356_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bcp.2016.03.023","volume":"109","author":"M Morissette","year":"2016","unstructured":"Morissette M, Morin N, Gr\u00e9goire L, Rajput A, Rajput AH, di Paolo T (2016) Brain \u03b17 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients. Biochem Pharmacol 109:62\u201369. https:\/\/doi.org\/10.1016\/j.bcp.2016.03.023","journal-title":"Biochem Pharmacol"},{"key":"1356_CR42","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1073\/pnas.1210984110","volume":"110","author":"F Akkus","year":"2013","unstructured":"Akkus F, Ametamey SM, Treyer V, Burger C, Johayem A, Umbricht D, Gomez Mancilla B, Sovago J et al (2013) Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography. Proc Natl Acad Sci U S A 110:737\u2013742. https:\/\/doi.org\/10.1073\/pnas.1210984110","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1356_CR43","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/ejn.13715","volume":"49","author":"Jose de Jesus Aceves Buendia","year":"2017","unstructured":"de Aceves Buendia JJ, Tiroshi L, Chiu WH, Goldberg JA (2017) Selective remodeling of glutamatergic transmission to striatal cholinergic interneurons after dopamine depletion. Eur J Neurosci. https:\/\/doi.org\/10.1111\/ejn.13715","journal-title":"European Journal of Neuroscience"},{"key":"1356_CR44","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.tips.2014.12.002","volume":"36","author":"KT Dineley","year":"2015","unstructured":"Dineley KT, Pandya AA, Yakel JL (2015) Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci 36:96\u2013108. https:\/\/doi.org\/10.1016\/j.tips.2014.12.002","journal-title":"Trends Pharmacol Sci"},{"key":"1356_CR45","doi-asserted-by":"publisher","first-page":"11973","DOI":"10.1523\/JNEUROSCI.2550-10.2010","volume":"30","author":"M Novak","year":"2010","unstructured":"Novak M, Halbout B, O\u2019Connor EC et al (2010) Incentive learning underlying cocaine-seeking requires mGluR5 receptors located on dopamine D1 receptor-expressing neurons. J Neurosci 30:11973\u201311982. https:\/\/doi.org\/10.1523\/JNEUROSCI.2550-10.2010","journal-title":"J Neurosci"},{"key":"1356_CR46","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1523\/JNEUROSCI.3184-17.2018","volume":"38","author":"LM Suarez","year":"2018","unstructured":"Suarez LM, Alberquilla S, Garc\u00eda-Montes JR, Moratalla R (2018) Differential synaptic remodeling by dopamine in direct and indirect striatal projection neurons in Pitx3\u2212\/\u2212 mice, a genetic model of Parkinson\u2019s disease. J Neurosci 38:3619\u20133630. https:\/\/doi.org\/10.1523\/JNEUROSCI.3184-17.2018","journal-title":"J Neurosci"},{"key":"1356_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.nbd.2014.09.010","volume":"73","author":"O Sol\u00eds","year":"2015","unstructured":"Sol\u00eds O, Espadas I, Del-Bel EA, Moratalla R (2015) Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(\u2212\/\u2212) aphakia mice. Neurobiol Dis 73:49\u201359. https:\/\/doi.org\/10.1016\/j.nbd.2014.09.010","journal-title":"Neurobiol Dis"},{"key":"1356_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nbd.2007.03.013","volume":"27","author":"Y Ding","year":"2007","unstructured":"Ding Y, Restrepo J, Won L, Hwang DY, Kim KS, Kang UJ (2007) Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson\u2019s disease. Neurobiol Dis 27:11\u201323. https:\/\/doi.org\/10.1016\/j.nbd.2007.03.013","journal-title":"Neurobiol Dis"},{"key":"1356_CR49","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1073\/pnas.1006511108","volume":"108","author":"Y Ding","year":"2011","unstructured":"Ding Y, Won L, Britt JP, Lim SAO, McGehee DS, Kang UJ (2011) Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice. Proc Natl Acad Sci U S A 108:840\u2013845. https:\/\/doi.org\/10.1073\/pnas.1006511108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1356_CR50","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1523\/JNEUROSCI.3718-04.2005","volume":"25","author":"D-Y Hwang","year":"2005","unstructured":"Hwang D-Y, Fleming SM, Ardayfio P et al (2005) 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson\u2019s disease. J Neurosci 25:2132\u20132137. https:\/\/doi.org\/10.1523\/JNEUROSCI.3718-04.2005","journal-title":"J Neurosci"},{"key":"1356_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2144\/000112517","volume":"43","author":"TJ Collins","year":"2007","unstructured":"Collins TJ (2007) ImageJ for microscopy. BioTechniques 43:25\u201330. https:\/\/doi.org\/10.2144\/000112517","journal-title":"BioTechniques"},{"key":"1356_CR52","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/mds.27119","volume":"32","author":"P Garc\u00eda-Sanz","year":"2017","unstructured":"Garc\u00eda-Sanz P, Orgaz L, Bueno-Gil G, Espadas I, Rodr\u00edguez-Traver E, Kulisevsky J, Gutierrez A, D\u00e1vila JC et al (2017) N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson\u2019s disease. Mov Disord 32:1409\u20131422. https:\/\/doi.org\/10.1002\/mds.27119","journal-title":"Mov Disord"},{"key":"1356_CR53","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.neuropharm.2013.03.038","volume":"71","author":"M Quik","year":"2013","unstructured":"Quik M, Campos C, Bordia T, Strachan JP, Zhang J, McIntosh JM, Letchworth S, Jordan K (2013) \u03b14\u03b22 nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology 71:191\u2013203. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.03.038","journal-title":"Neuropharmacology"},{"key":"1356_CR54","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.neuropharm.2012.04.029","volume":"63","author":"M Quik","year":"2012","unstructured":"Quik M, Park KM, Hrachova M, Mallela A, Huang LZ, McIntosh JM, Grady SR (2012) Role for \u03b16 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice. Neuropharmacology 63:450\u2013459. https:\/\/doi.org\/10.1016\/j.neuropharm.2012.04.029","journal-title":"Neuropharmacology"},{"key":"1356_CR55","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1021\/jm401622k","volume":"57","author":"L Zhang","year":"2014","unstructured":"Zhang L, Balan G, Barreiro G, Boscoe BP, Chenard LK, Cianfrogna J, Claffey MM, Chen L et al (2014) Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. J Med Chem 57:861\u2013877. https:\/\/doi.org\/10.1021\/jm401622k","journal-title":"J Med Chem"},{"key":"1356_CR56","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/jnr.20489","volume":"80","author":"MR Domenici","year":"2005","unstructured":"Domenici MR, Potenza RL, Martire A, Coccurello R, P\u00e8zzola A, Reggio R, Tebano MT, Popoli P (2005) Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson\u2019s disease. J Neurosci Res 80:646\u2013654. https:\/\/doi.org\/10.1002\/jnr.20489","journal-title":"J Neurosci Res"},{"key":"1356_CR57","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1471-4159.2010.06635.x","volume":"113","author":"B Ouattara","year":"2010","unstructured":"Ouattara B, Gasparini F, Morissette M, Gr\u00e9goire L, Samadi P, Gomez-Mancilla B, di Paolo T (2010) Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. J Neurochem 113:715\u2013724. https:\/\/doi.org\/10.1111\/j.1471-4159.2010.06635.x","journal-title":"J Neurochem"},{"key":"1356_CR58","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.parkreldis.2014.05.003","volume":"20","author":"O Rascol","year":"2014","unstructured":"Rascol O, Fox S, Gasparini F, Kenney C, di Paolo T, Gomez-Mancilla B (2014) Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord 20:947\u2013956. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.05.003","journal-title":"Parkinsonism Relat Disord"},{"key":"1356_CR59","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.coph.2018.03.003","volume":"38","author":"I Sebastianutto","year":"2018","unstructured":"Sebastianutto I, Cenci MA (2018) mGlu receptors in the treatment of Parkinson\u2019s disease and L-DOPA-induced dyskinesia. Curr Opin Pharmacol 38:81\u201389. https:\/\/doi.org\/10.1016\/j.coph.2018.03.003","journal-title":"Curr Opin Pharmacol"},{"key":"1356_CR60","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.biopsych.2005.05.044","volume":"59","author":"N Pav\u00f3n","year":"2006","unstructured":"Pav\u00f3n N, Mart\u00edn AB, Mendialdua A, Moratalla R (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59:64\u201374. https:\/\/doi.org\/10.1016\/j.biopsych.2005.05.044","journal-title":"Biol Psychiatry"},{"key":"1356_CR61","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.biopsych.2006.11.032","volume":"62","author":"JE Westin","year":"2007","unstructured":"Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA (2007) Spatiotemporal pattern of striatal ERK1\/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 62:800\u2013810. https:\/\/doi.org\/10.1016\/j.biopsych.2006.11.032","journal-title":"Biol Psychiatry"},{"key":"1356_CR62","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.biopsych.2013.05.006","volume":"75","author":"LM Su\u00e1rez","year":"2014","unstructured":"Su\u00e1rez LM, Sol\u00eds O, Caram\u00e9s JM, Taravini IR, Sol\u00eds JM, Murer MG, Moratalla R (2014) L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. Biol Psychiatry 75:711\u2013722. https:\/\/doi.org\/10.1016\/j.biopsych.2013.05.006","journal-title":"Biol Psychiatry"},{"key":"1356_CR63","doi-asserted-by":"publisher","first-page":"35827","DOI":"10.1074\/jbc.M109.046276","volume":"284","author":"Y-JI Jong","year":"2009","unstructured":"Jong Y-JI, Kumar V, O\u2019Malley KL (2009) Intracellular metabotropic glutamate receptor 5 (mGluR5) activates signaling cascades distinct from cell surface counterparts. J Biol Chem 284:35827\u201335838. https:\/\/doi.org\/10.1074\/jbc.M109.046276","journal-title":"J Biol Chem"},{"key":"1356_CR64","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","volume":"39","author":"D Rylander","year":"2010","unstructured":"Rylander D, Iderberg H, Li Q, Dekundy A, Zhang J, Li H, Baishen R, Danysz W et al (2010) A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 39:352\u2013361. https:\/\/doi.org\/10.1016\/j.nbd.2010.05.001","journal-title":"Neurobiol Dis"},{"key":"1356_CR65","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.biopsych.2015.02.027","volume":"79","author":"F Akkus","year":"2016","unstructured":"Akkus F, Treyer V, Johayem A, Ametamey SM, Mancilla BG, Sovago J, Buck A, Hasler G (2016) Association of long-term nicotine abstinence with normal metabotropic glutamate receptor-5 binding. Biol Psychiatry 79:474\u2013480. https:\/\/doi.org\/10.1016\/j.biopsych.2015.02.027","journal-title":"Biol Psychiatry"},{"key":"1356_CR66","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1749-6632.1996.tb34445.x","volume":"777","author":"S Shimohama","year":"1996","unstructured":"Shimohama S, Akaike A, Kimura J (1996) Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation. Ann N Y Acad Sci 777:356\u2013361","journal-title":"Ann N Y Acad Sci"},{"key":"1356_CR67","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0022-3565(24)38944-X","volume":"295","author":"BH Tonnessen","year":"2000","unstructured":"Tonnessen BH, Severson SR, Hurt RD, Miller VM (2000) Modulation of nitric-oxide synthase by nicotine. J Pharmacol Exp Ther 295:601\u2013606","journal-title":"J Pharmacol Exp Ther"},{"key":"1356_CR68","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/jnr.10158","volume":"67","author":"E Weruaga","year":"2002","unstructured":"Weruaga E, Balkan B, Koylu EO, Pogun S, Alonso JR (2002) Effects of chronic nicotine administration on nitric oxide synthase expression and activity in rat brain. J Neurosci Res 67:689\u2013697. https:\/\/doi.org\/10.1002\/jnr.10158","journal-title":"J Neurosci Res"},{"key":"1356_CR69","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/j.1460-9568.2008.06387.x","volume":"28","author":"M Giorgi","year":"2008","unstructured":"Giorgi M, D\u2019Angelo V, Esposito Z, Nuccetelli V, Sorge R, Martorana A, Stefani A, Bernardi G et al (2008) Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci 28:941\u2013950. https:\/\/doi.org\/10.1111\/j.1460-9568.2008.06387.x","journal-title":"Eur J Neurosci"},{"key":"1356_CR70","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/brain\/awq342","volume":"134","author":"B Picconi","year":"2011","unstructured":"Picconi B, Bagetta V, Ghiglieri V, Paill\u00e8 V, di Filippo M, Pendolino V, Tozzi A, Giamp\u00e0 C et al (2011) Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 134:375\u2013387. https:\/\/doi.org\/10.1093\/brain\/awq342","journal-title":"Brain"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-018-1356-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-018-1356-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-018-1356-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T16:28:43Z","timestamp":1755707323000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-018-1356-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1356"],"URL":"https:\/\/doi.org\/10.1007\/s12035-018-1356-6","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]},"assertion":[{"value":"29 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments were conducted in accordance with the guidelines of the European Union Council Directive (86\/609\/EEC and 2003\/65\/CE). The protocol was approved by the Spanish Council ethics committee and the committee of ethics and animal experimentation of the Instituto Cajal (CSIC).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}}]}}